Advisors Capital Management LLC purchased a new position in shares of Avantor, Inc. (NYSE:AVTR - Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 441,317 shares of the company's stock, valued at approximately $4,369,000. Advisors Capital Management LLC owned about 0.07% of Avantor at the end of the most recent quarter.
A number of other institutional investors have also bought and sold shares of the business. Private Management Group Inc. grew its holdings in shares of Avantor by 50.4% during the fourth quarter. Private Management Group Inc. now owns 2,456,859 shares of the company's stock worth $28,156,000 after purchasing an additional 823,572 shares during the last quarter. GSA Capital Partners LLP acquired a new position in Avantor in the second quarter valued at $800,000. Assenagon Asset Management S.A. increased its stake in Avantor by 425.0% in the second quarter. Assenagon Asset Management S.A. now owns 556,871 shares of the company's stock valued at $5,513,000 after purchasing an additional 450,801 shares during the period. Oppenheimer Asset Management Inc. purchased a new stake in shares of Avantor in the second quarter valued at about $805,000. Finally, Brickwood Asset Management LLP boosted its stake in shares of Avantor by 6,891.9% during the fourth quarter. Brickwood Asset Management LLP now owns 3,184,043 shares of the company's stock worth $36,489,000 after buying an additional 3,138,504 shares during the period. 95.08% of the stock is owned by hedge funds and other institutional investors.
Avantor Stock Performance
Shares of NYSE AVTR opened at $14.45 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.78 and a debt-to-equity ratio of 0.65. The firm's 50-day moving average price is $11.63 and its two-hundred day moving average price is $9.65. Avantor, Inc. has a 52-week low of $7.26 and a 52-week high of $15.93. The stock has a market capitalization of $9.77 billion, a P/E ratio of -17.20, a P/E/G ratio of 10.76 and a beta of 0.89.
Avantor (NYSE:AVTR - Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The company reported $0.21 earnings per share for the quarter, topping analysts' consensus estimates of $0.19 by $0.02. The business had revenue of $1.69 billion for the quarter, compared to analysts' expectations of $1.61 billion. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.The business's quarterly revenue was up .5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.24 EPS. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. As a group, sell-side analysts forecast that Avantor, Inc. will post 0.81 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on AVTR. Jefferies Financial Group raised Avantor from an "underperform" rating to a "hold" rating and set a $13.00 price target for the company in a report on Wednesday, July 29th. TD Cowen reissued a "hold" rating on shares of Avantor in a research report on Wednesday, July 15th. UBS Group set a $8.00 target price on Avantor in a research note on Wednesday, June 24th. Wall Street Zen upgraded Avantor from a "hold" rating to a "buy" rating in a research report on Saturday, June 27th. Finally, Morgan Stanley upped their price objective on shares of Avantor from $10.00 to $14.00 and gave the company an "equal weight" rating in a research note on Thursday, July 30th. Two investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $12.00.
Check Out Our Latest Analysis on Avantor
About Avantor
(
Free Report)
Avantor, Inc NYSE: AVTR is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.
Avantor's offerings are organized across two primary segments.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Avantor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avantor wasn't on the list.
While Avantor currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
